Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine

Journal of Nuclear Medicine

Volumn 39, Issue 12, 1998, Pages 2190-2192

  Silberstein, Edward B ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Adverse reactions; PET; Radiopharmaceuticals

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

ARTICLE; CLINICAL ARTICLE; HUMAN; NOMENCLATURE; POSITRON; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE DISTRIBUTION; SIDE EFFECT;

HUMANS; NUCLEAR MEDICINE; PREVALENCE; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032407610     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. U.S. Code of Federal Regulations. Title 21, part 310.305.
2. Delamothe T. Reporting adverse drug reactions. Br Med J 1992;304:465.
3. Silberstein EB, Ryan J. Prevalence of adverse reactions in Nuclear Medicine. J Nucl Med 1996;37:185-192.